Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients

Deletions and mutations affecting lymphoid transcription factor IKZF1 (IKAROS) are associated with an increased relapse risk and poor outcome in B-cell precursor acute lymphoblastic leukemia. However, additional genetic events may either enhance or negate the effects of IKZF1 deletions on prognosis. In a large discovery cohort of 533 childhood B-cell precursor acute lymphoblastic leukemia patients, we observed that single-copy losses of BTG1 were significantly enriched in IKZF1-deleted B-cell precursor acute lymphoblastic leukemia (P=0.007). While BTG1 deletions alone had no impact on prognosis, the combined presence of BTG1 and IKZF1 deletions was associated with a significantly lower 5-year event-free survival (P=0.0003) and a higher 5-year cumulative incidence of relapse (P=0.005), when compared with IKZF1-deleted cases without BTG1 aberrations. In contrast, other copy number losses commonly observed in B-cell precursor acute lymphoblastic leukemia, such as CDKN2A/B, PAX5, EBF1 or RB1, did not affect the outcome of IKZF1-deleted acute lymphoblastic leukemia patients. To establish whether the combined loss of IKZF1 and BTG1 function cooperate in leukemogenesis, Btg1-deficient mice were crossed onto an Ikzf1 heterozygous background. We observed that loss of Btg1 increased the tumor incidence of Ikzf1+/− mice in a dose-dependent manner. Moreover, murine B cells deficient for Btg1 and Ikzf1+/− displayed increased resistance to glucocorticoids, but not to other chemotherapeutic drugs. Together, our results identify BTG1 as a tumor suppressor in leukemia that, when deleted, strongly enhances the risk of relapse in IKZF1-deleted B-cell precursor acute lymphoblastic leukemia, and augments the glucocorticoid resistance phenotype mediated by the loss of IKZF1 function.

[1]  Diane Uschner,et al.  Randomization: The forgotten component of the randomized clinical trial , 2018, Statistics in medicine.

[2]  M. D. Den Boer,et al.  Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. , 2016, Blood.

[3]  R. Pieters,et al.  Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia , 2016, Leukemia.

[4]  B. Scheijen,et al.  Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development , 2016, Haematologica.

[5]  Taosheng Chen,et al.  Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. , 2015, Cancer cell.

[6]  T. Fioretos,et al.  Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their synergistic transformation by Pax5 haploinsufficiency. , 2015, Blood.

[7]  C. Mullighan,et al.  Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. , 2015, Blood.

[8]  B. Meissner,et al.  ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia , 2015, Leukemia.

[9]  T. Révész,et al.  Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia , 2015, British journal of haematology.

[10]  J. Downing,et al.  Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Wade,et al.  A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. , 2014, Blood.

[12]  Q. Wang,et al.  High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia. , 2014, Cancer genetics.

[13]  M. D. Den Boer,et al.  IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. , 2014, Blood.

[14]  W. Evans,et al.  Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. , 2013, Blood.

[15]  B. Scheijen,et al.  B-lineage transcription factors and cooperating gene lesions required for leukemia development , 2013, Leukemia.

[16]  R. Pieters,et al.  High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation , 2013, Leukemia.

[17]  M. Costanzi,et al.  Btg1 is Required to Maintain the Pool of Stem and Progenitor Cells of the Dentate Gyrus and Subventricular Zone , 2012, Front. Neurosci..

[18]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[19]  R. Kuiper,et al.  The Origin and Nature of Tightly Clustered BTG1 Deletions in Precursor B-Cell Acute Lymphoblastic Leukemia Support a Model of Multiclonal Evolution , 2012, PLoS genetics.

[20]  Michael N. Edmonson,et al.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[21]  A. Fischer,et al.  Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-lymphoblastic leukemia. , 2011, Blood.

[22]  P. Kastner,et al.  Role of Ikaros in T-cell acute lymphoblastic leukemia. , 2011, World journal of biological chemistry.

[23]  Hein Putter,et al.  mstate: An R Package for the Analysis of Competing Risks and Multi-State Models , 2011 .

[24]  C. V. D. Schoot,et al.  Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia , 2011, Leukemia.

[25]  A. Veerman,et al.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL , 2010, Leukemia.

[26]  Christian Gilissen,et al.  BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. , 2010, Blood.

[27]  F. Sigaux,et al.  Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia , 2010, Leukemia.

[28]  K. Shokat,et al.  Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents , 2010, Proceedings of the National Academy of Sciences.

[29]  E. Cameron,et al.  Conditional expression and oncogenicity of c‐myc linked to a CD2 gene dominant control region , 2009, International journal of cancer.

[30]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[31]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[32]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[33]  S. Tsuzuki,et al.  Genetic abnormalities involved in t(12;21) TEL–AML1 acute lymphoblastic leukemia: Analysis by means of array‐based comparative genomic hybridization , 2007, Cancer science.

[34]  J. Hehir-Kwa,et al.  High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression , 2007, Leukemia.

[35]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[36]  A. Ferrando,et al.  Activating Notch1 mutations are an early event in T-cell malignancy of Ikaros point mutant Plastic/+ mice. , 2007, Leukemia research.

[37]  P. Kastner,et al.  Notch Activation Is an Early and Critical Event during T-Cell Leukemogenesis in Ikaros-Deficient Mice , 2006, Molecular and Cellular Biology.

[38]  M. Schebesta,et al.  Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. , 2002, Immunity.

[39]  C. Murre,et al.  Disruption of pre-TCR expression accelerates lymphomagenesis in E2A-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Murre,et al.  IL‐7Rα and E47: independent pathways required for development of multipotent lymphoid progenitors , 2002, The EMBO journal.

[41]  J. Ward,et al.  Pathology of Aging B6;129 Mice , 2001, Toxicologic pathology.

[42]  C. Murre,et al.  Early Thymocyte Development Is Regulated by Modulation of E2a Protein Activity , 2001, The Journal of experimental medicine.

[43]  D. Pinkel,et al.  E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas , 1997, Molecular and cellular biology.

[44]  A. Sharpe,et al.  Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. , 1996, Immunity.

[45]  A. Mccarthy.  Development , 1996, Current Opinion in Neurobiology.

[46]  K. Georgopoulos,et al.  A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma , 1995, Cell.

[47]  A. Sharpe,et al.  The ikaros gene is required for the development of all lymphoid lineages , 1994, Cell.

[48]  F. Sigaux,et al.  An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions , 2014, Leukemia.

[49]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.